Beam Therapeutics INC Schedule 13G passive stakes

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.95% of Beam Therapeutics Inc. common stock as of June 30, 2026.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 9.99% of Beam Therapeutics Inc.'s common stock, as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership of 5.02% in Beam Therapeutics Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G for Beam Therapeutics Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

State Street Corporation has reported a 5.2% beneficial ownership stake in Beam Therapeutics Inc., holding over 5.2 million common shares.

Farallon Capital Management and its affiliates updated their beneficial ownership in Beam Therapeutics Inc. to 9.99%, reflecting internal management changes.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.6% beneficial ownership stake in Beam Therapeutics Inc. as of December 31, 2025.

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 6 to Schedule 13G, disclosing a combined beneficial ownership of 12.29% in Beam Therapeutics Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 13.6% beneficial ownership stake in Beam Therapeutics Inc. as of September 30, 2025.

ARK Investment Management LLC and Catherine D. Wood have increased their beneficial ownership in Beam Therapeutics Inc. to 10.35% of common stock.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 15.0% beneficial ownership stake in Beam Therapeutics Inc. common stock as of June 30, 2025.

ARCH Venture Funds and their managing directors have filed an amended Schedule 13G, disclosing their updated beneficial ownership of Beam Therapeutics Inc. common stock, collectively holding approximately 4.5% to 4.6% of the class as of March 31, 2025.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 9.99% in Beam Therapeutics Inc. common stock, including shares and exercisable warrants.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.5% in Beam Therapeutics Inc. as of March 31, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reaffirming their beneficial ownership of 10.1% of Beam Therapeutics Inc.'s common stock as of March 31, 2025.

ARCH Venture Fund entities and their managing directors have disclosed a continued beneficial ownership of approximately 5.5% of Beam Therapeutics Inc.'s common stock as of December 31, 2024.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Beam Therapeutics Inc. as of December 31, 2024.

Farallon Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of up to 9.9% of Beam Therapeutics Inc.'s common stock as of December 31, 2024.

ARK Investment Management LLC has filed an amended Schedule 13G, reporting a 7.92% beneficial ownership stake in Beam Therapeutics Inc. as of September 30, 2024.